Champions Oncology, Inc. (FRA:2I3)
Germany flag Germany · Delayed Price · Currency is EUR
5.05
+0.07 (1.41%)
At close: Dec 5, 2025

Champions Oncology Company Description

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States.

The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.

It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies.

In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies.

It markets its products through internet and sales force to pharmaceutical and biotechnology companies.

The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011.

Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Champions Oncology, Inc.
Country United States
Founded 1985
Industry Biological Products, Except Diagnostic Substances
Employees 213
CEO Robert Brainin

Contact Details

Address:
One University Plaza
Hackensack, Delaware 07601
United States
Phone 201 808 8400
Website championsoncology.com

Stock Details

Ticker Symbol 2I3
Exchange Frankfurt Stock Exchange
Stock Type Common Stock
Fiscal Year May - April
Reporting Currency USD
SIC Code 2836

Key Executives

Name Position
Robert Brainin Chief Executive Officer
David Miller Chief Financial Officer
Maria Mancini Chief Operating Officer